**DESCRIPTION**

**Species Reactivity**
Human

**Specificity**
Detects human TNF-α in direct ELISAs and Western blots.

**Source**
Polyclonal Goat IgG

**Purification**
Antigen Affinity-purified

**Immunogen**
*E. coli*-derived recombinant human TNF-α
Val77-Leu233
Accession # P01375

**Endotoxin Level**
<0.10 EU per 1 μg of the antibody by the LAL method.

**Formulation**
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

*Small pack size (-SP) is supplied either lyophilized or as a 0.2 μm filtered solution in PBS.

**APPLICATIONS**

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

<table>
<thead>
<tr>
<th>Recommended Concentration</th>
<th>Sample</th>
</tr>
</thead>
<tbody>
<tr>
<td>Western Blot</td>
<td>0.1 µg/mL</td>
</tr>
<tr>
<td>Immunocytochemistry</td>
<td>5-15 µg/mL</td>
</tr>
<tr>
<td>Neutralization</td>
<td>Measured by its ability to neutralize TNF-α-induced cytotoxicity in the L-929 mouse fibroblast cell line. Matthews, N. and M. L. Neale (1987) in Lymphokines and Interferons, A Practical Approach. Clemens, M. J. et al. (eds): IRL Press. 221. The Neutralization Dose (ND₅₀) is typically 0.01-0.06 μg/ml in the presence of 1.5 ng/mL Recombinant Human TNF-α.</td>
</tr>
</tbody>
</table>

**DATA**

**Neutralization**

Cytotoxicity Induced by TNF-α and Neutralization by Human TNF-α Antibody. Recombinant Human TNF-α (Catalog # 210-TA) induces cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line). Cytotoxicity elicited by Recombinant Human TNF-α (1.5 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human TNF-α Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-210-NA). The ND₅₀ is typically 0.01-0.06 μg/mL.

**Immunocytochemistry**

TNF-α in Human PBMCs. TNF-α was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) using Goat Anti-Human TNF-α Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-210-NA) at 5 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Non-adherent Cells.

**PREPARATION AND STORAGE**

**Reconstitution**
Reconstitute at 0.2 mg/mL in sterile PBS.

**Shipping**
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

*Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C.

**Stability & Storage**
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Rev. 1/3/2020 Page 1 of 2
Tumor necrosis factor alpha (TNF-alpha, TNF-α, TNFA), also known as Cachectin and TNFSF2, is the prototypic ligand of the TNF superfamily. It is a pleiotropic molecule that plays a central role in inflammation, immune system development, apoptosis, and lipid metabolism. TNF- is produced by several lymphoid cells as well as by astrocytes, endothelial cells, and smooth muscle cells. Human TNF-alpha consists of a 35 amino acid (aa) cytoplasmic domain, a 21 aa transmembrane segment, and a 177 aa extracellular domain (ECD). Within the ECD, human TNF-alpha shares 97% aa sequence identity with rhesus and 71%-92% with bovine, canine, cotton rat, equine, feline, mouse, porcine, and rat TNF-alpha. TNF-alpha is produced by a wide variety of immune, epithelial, endothelial, and tumor cells. TNF-alpha is assembled intracellularly to form a noncovalently linked homotrimer which is expressed on the cell surface. Cell surface TNF-alpha can induce the lysis of neighboring tumor cells and virus infected cells, and it can generate its own downstream cell signaling following ligation by soluble TNFR I. Shedding of membrane bound TNF-alpha by TACE/ADAM17 releases the bioactive cytokine, a 55 kDa molecular weight soluble trimer of the TNF-alpha extracellular domain. TNF-alpha binds the ubiquitous 55-60 kDa TNF RI and the hematopoietic cell-restricted 80 kDa TNF RII, both of which are also expressed as homotrimers present on virtually all cell types. Both type I and type II receptors bind TNF-alpha with comparable affinity, although only TNF RII contains a cytoplasmic death domain which triggers the activation of apoptosis. Soluble forms of both types of receptors are released and can neutralize the biological activity of TNF-alpha.